Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Publication/Presentation Date
11-2023
Published In/Presented At
Kalunian K, Levin R, Parameswaran S, kopyt n, Connelly S, Sun E, Kim K, fung m, Rathi M. Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Article
COinS
